More powers for European Parliament in time for ATMP (Advanced Therapies Medicinal Products) implementation?
This article was originally published in Clinica
Executive Summary
The European Parliament looks close to gaining the increased powers it desires - and in time to have an influence on implementation of the proposed Advanced Therapies Medicinal Products (ATMP) Regulation, after the text has been adopted. This ATMP Regulation will cover at least some human tissue engineered products, as well as cell and gene therapy products. MEPs have long complained that they have no further say, once their role in the approval of a Directive or Regulation is over, in how the legislation is implemented by way of technical operating rules through "comitology". This is a task delegated to the Commission, acting on the advice of 248 expert committees, often composed of national civil servants. Council then decides whether to approve the rules.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.